Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
But launch is unlikely before 2024.
Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
Yet another makeover raises fresh questions over Bellicum’s technology and sees its valuation haemorrhage some more.
With Gilead's big sellers forecast to drift, investors turn to its newer projects but find little comfort.
Bamlanivimab bucks could help Lilly bounce back from a soft third quarter, but diabetes is the big focus.
The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
The effort has implications for international travel and allocating vaccines – but the precise quantitative tests necessary for this do not, as yet, exist.
Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.